Published online Apr 27, 2014. doi: 10.4254/wjh.v6.i4.178
Revised: March 5, 2014
Accepted: March 13, 2014
Published online: April 27, 2014
Core tip: Combination of primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD) has recently arisen as a challenging research field. Recent data highlight the specific clinical and genetic traits that differentiate PSC-IBD from the two diseases individually. We reviewed the literature on colorectal neoplastic susceptibility in this subset of patients and the underlying pathogenetic mechanisms. We also emphasize the technological advances that have provided novel diagnostic tools for more accurate detection of dysplastic lesions. Finally, we present current guidelines on follow-up as well as all evidence available as to whether ursodeoxycholic acid should be used prophylactically against colorectal cancer.